title: In vitro activity of tigecycline and comparators against gram-negative bacteria isolated from a tertiary hospital in Alexandria, Egypt.
abstract: The emergence of infections caused by multidrug-resistant Gram-negative bacteria, in particular Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, has necessitated the search for alternative therapy by either introducing new agents or renewing interest in old agents. This study compares the in vitro activity of tigecycline (TIG), recently introduced to Egyptian market, to other potentially active antimicrobials as Colistin (COL), imipenem (IPM), levofloxacin (LEV), and piperacillin/tazobactam (PIP/TAZ) against 67 Gram-negative clinical isolates obtained from El- Meery Hospital in Alexandria, Egypt. El-Meery Hospital is a 1,500-bed tertiary teaching hospital where TIG has not been previously used. Based on MIC(90)s, TIG was found to be a comparator to IPM and COL (MIC(90)= 8 μg/ml). LEV and PIP/TAZ were less active than TIG exhibiting high MIC(90)s. TIG inhibited 100% of Escherichia coli and K. pneumoniae and 60% of Ps. aeruginosa and A. baumannii isolates. In time-kill studies against IPM-resistant isolates, TIG showed bactericidal activity after 6 hours of contact against the Enterobacteriaceae isolates and after 3 hours for the tested Ps. aeruginosa isolates at 4× and 8× MIC. Against A. baumannii, TIG exerted a bacteriostatic effect. TIG demonstrated variable ability to suppress biofilm formation affecting mainly E. coli and A. baumannii isolates. These results point TIG to be a promising agent in treatment of infections caused by strains for which adequate therapy has been limited. As far as we know, this is the first report evaluating the in vitro activity of TIG against Egyptian clinical isolates.
authors.affiliation: Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Alexandria University, El-Khartoom Square, Azarita, Alexandria, Egypt. neli.mohamed@alexpharmacy.edu.eg
authors.forename: Nelly M
authors.initials: NM
authors.lastname: Mohamed
authors.forename: Alaa A F
authors.initials: AA
authors.lastname: Youssef
mesh_terms: D040981:Acinetobacter baumannii / Q000145:classification / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects / Q000254:growth & development; D024901:Drug Resistance, Multiple, Bacterial; D004534:Egypt; D004926:Escherichia coli / Q000145:classification / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D006090:Gram-Negative Bacteria / Q000145:classification / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification*; D016905:Gram-Negative Bacterial Infections / Q000382:microbiology*; D006784:Hospitals, Teaching; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000592:standards; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline